SNT-5382 / Syntara, Synairgen - LARVOL DELTA

Structure-guided computational identification of novel competitive inhibitors targeting the human LOXL2 active site | Poster Board #1318 (ACS-Fall 2026) - "A series of novel inhibitors was developed using the scaffolds of SNT-5382, PXS-5505, and PAT-1251 as structural baselines. Superior binding affinities and Induced Fit Scores, relative to existing benchmarks, were demonstrated through computational validation of specific scaffold modifications. A translational path for the development of high-affinity inhibitors designed to attenuate fibrosis across varying disease severities is provided by these findings."

Fibrosis • Immunology

Structure-guided computational identification of novel competitive inhibitors targeting the human LOXL2 active site | Poster Board #1738 (ACS-Fall 2026) - "A series of novel inhibitors was developed using the scaffolds of SNT-5382, PXS-5505, and PAT-1251 as structural baselines. Superior binding affinities and Induced Fit Scores, relative to existing benchmarks, were demonstrated through computational validation of specific scaffold modifications. A translational path for the development of high-affinity inhibitors designed to attenuate fibrosis across varying disease severities is provided by these findings."

Fibrosis • Immunology

The small molecule LOXL2 inhibitor SNT-5382 reduces cardiac fibrosis and achieves strong clinical target engagement. (PubMed, Sci Rep) - P1 | "SNT-5382 exhibited potent anti-fibrotic efficacy in a MI model and sustained clinical target engagement.Trial registration: Australian New Zealand Clinical Trials Registry identifier: ACTRN12617001564347. Registered 21 November 2017- registered, https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12617001564347."

Journal • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Hypertension • Immunology • Myocardial Infarction

Lysyl oxidase inhibitors attenuate cyclosporin A-induced nephropathy in mouse. (PubMed, Sci Rep) - "At 8 weeks, CsA-treated animals were divided into 5 groups respectively treated with: (1) vehicle, (2) PXS-5505 (Pan-LOX inhibitor), (3) PXS-5382 (LOX-like 2 inhibitor), (4) PXS-5505 for 4 weeks then PXS-5382 for 4 weeks (sequential therapy), and (5) Telmisartan (standard therapy). Among all regimens including telmisartan, only Pan-LOX inhibitor PXS-5505 was able to attenuate uraemia. Collectively, our study suggests that Pan-LOX and LOXL2 inhibition can attenuate progressive nephropathy due to CsA administration."

Journal • Preclinical • Fibrosis • Immunology • Inflammation • Nephrology • Renal Disease • Solid Organ Transplantation • Transplantation • MMP2 • SMAD3 • TGFB1 • TNFA